Table 2.

Tyrosine kinase inhibitors with KIT inhibitory activity tested in clinical trials in patients with gastrointestinal stromal tumor.

	Study	Setting	Phase	N	ORR (%)	PFS (months)
Sorafenib	Park et al. [2012]	≥Third line	II	31	13	4.9
	Kindler et al. [2011]	≥Second line	II	38	13	5.2
Nilotinib	Cauchi et al. [2012]	Third line	II	13	0	6
	Sawaki et al. [2011]	Third line	II	35	3	3.7
	Reichardt et al. [2012]	Third line	III	165	<1	3.6
	Blay et al. [2013]	First line	III	324	NA	25.9
Masitinib	Le Cesne et al. [2010]	First line	II	30	41.3	41.3

N, number of patients treated with the corresponding drug; NA, not available; ORR, overall response rate; PFS, progression-free survival.